Show simple item record

dc.contributor.authorIyer, Vidyashankara
dc.contributor.authorHu, Lei
dc.contributor.authorSchante, Carole E.
dc.contributor.authorVance, David
dc.contributor.authorChadwick, Chrystal
dc.contributor.authorJain, Nishant Kumar
dc.contributor.authorBrey, Robert N.
dc.contributor.authorJoshi, Sangeeta B.
dc.contributor.authorVolkin, David B.
dc.contributor.authorAndra, Kiran K.
dc.contributor.authorBann, James G.
dc.contributor.authorMantis, Nicholas J.
dc.contributor.authorMiddaugh, C. Russell
dc.date.accessioned2014-03-03T01:08:04Z
dc.date.available2014-03-03T01:08:04Z
dc.date.issued2013-11
dc.identifier.citationIyer, Vidyashankara; Hu, Lei; Schante, Carole E.; Vance, David; Chadwick, Chrystal; Jain, Nishant Kumar; Brey, Robert N.; Joshi, Sangeeta B.; Volkin, David B.; Andra, Kiran K.; Bann, James G.; Mantis, Nicholas J.; Middaugh, C. Russell. 2013. Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine. Human Vaccines & Immunotherapeutics, vol. 9:no. 11:ppg. 2362-2370en_US
dc.identifier.issn2164-5515
dc.identifier.otherWOS:000330382300019
dc.identifier.urihttp://dx.doi.org/10.4161/hv.25852
dc.identifier.urihttp://hdl.handle.net/10057/7096
dc.descriptionClick on the DOI link to access the article (may not be free).en_US
dc.description.abstractDominant negative inhibitor (DNI) is a translocation-deficient homolog of recombinant protective antigen of Bacillus anthracis that is a candidate for a next generation anthrax vaccine. This study demonstrates that the biophysical characteristics of the DNI protein stored in lyophilized form at 4 degrees C for 8 y were similar to recombinant protective antigen (rPA). To provide information on the accelerated stability of DNI, samples in the lyophilized form were subjected to thermal stress (40 and 70 degrees C for up to 4 weeks) and thoroughly evaluated using various biophysical and chemical characterization techniques. Results demonstrate preserved structural stability of the DNI protein under extreme conditions, suggesting long-term stability can be achieved for a vaccine that employs DNI, as desired for a biodefense countermeasure. Furthermore, the biological activity of the stressed DNI bound to the adjuvant Alhydrogel (R) was evaluated in mice and it was found that the immunogenicity of DNI was not affected by thermal stress.en_US
dc.description.sponsorshipNIH/NIAID U01AI082210 (to RNB). We would like to thank Dr Karen Chave of the Northeast Biodefense Center's (NBC) Protein Expression Core at the Wadsworth Center (supported by award 5 U54-AI057158-10 from the NIH) for providing us with lethal factor and recombinant PA.en_US
dc.language.isoen_USen_US
dc.publisherLandes Bioscienceen_US
dc.relation.ispartofseriesHuman Vaccines & Immunotherapeutics;v.9:no.11
dc.subjectDominant-negative inhibitoren_US
dc.subjectVaccineen_US
dc.subjectAluminum hydroxideen_US
dc.subjectImmunogenicityen_US
dc.subjectAccelerated stabilityen_US
dc.subjectBiophysical characterizationen_US
dc.titleBiophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccineen_US
dc.typeArticleen_US
dc.rights.holderCopyright 2013 Landes Bioscience


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record